A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of Type 1 diabetes in NOD mice

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 187-198

  Bhattacharya, Palash ^a   Fan, Jilao ^a   Haddad, Christine ^a   Essani, Abdul ^a   Gopisetty, Anupama ^a   Elshabrawy, Hatem A ^a   Vasu, Chenthamarakshan ^b   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anti CTLA 4; Anti Glut2; Dendritic cells; Diabetes; Regulatory T cells; Tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; BISPECIFIC ANTIBODY; CELL ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 2 MONOCLONAL ANTIBODY; INSULIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TARGET ORGAN;

ANTI-CTLA-4; ANTI-GLUT2; DENDRITIC CELLS; DIABETES; REGULATORY T CELLS; TOLERANCE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CELL LINE; CRICETINAE; CTLA-4 ANTIGEN; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE TRANSPORTER TYPE 2; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84900810225     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.04.014     Document Type: Article

References (47)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358(9277):221-229.
2. Todd J.A., Wicker L.S. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001, 15(3):387-395.
3. Yoon J.W., Jun H.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann. N. Y. Acad. Sci. 2001, 928:200-211.
4. Kukreja A., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002, 109(1):131-140.
5. Skarsvik S., et al. Poor in vitro maturation and pro-inflammatory cytokine response of dendritic cells in children at genetic risk of type 1 diabetes. Scand. J. Immunol. 2004, 60(6):647-652.
6. Bluestone J.A. Is CTLA-4 a master switch for peripheral T cell tolerance?. J. Immunol. 1997, 158(5):1989-1993.
7. Lindley S., et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54(1):92-99.
8. Alard P., et al. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 2006, 55(7):2098-2105.
9. Araki M., et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J. Immunol. 2009, 183(8):5146-5157.
10. Yadav D., et al. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cell. Immunol. 2009, 258(2):161-171.
11. Maini R.N., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41(9):1552-1563.
12. Maini R., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354(9194):1932-1939.
13. Silva L.C., Ortigosa L.C., Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010, 2(6):817-833.
14. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 2003, 3(2):123-132.
15. Chung D.T., et al. Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. Int. Immunol. 2007, 19(8):1003-1010.
16. Masteller E.L., et al. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol. 2005, 175(5):3053-3059.
17. Masteller E.L., et al. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J. Immunol. 2003, 171(10):5587-5595.
18. Linsley P.S., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1(9):793-801.
19. Tivol E.A., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
20. Linsley P.S., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991, 174(3):561-569.
21. Saverino D., et al. Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J. Immunol. 2002, 168(1):207-215.
22. Londrigan S.L., et al. In situ protection against islet allograft rejection by CTLA4Ig transduction. Transplantation 2010, 90(9):951-957.
23. Vergani A., et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 2010, 59(9):2253-2264.
24. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002, 2(2):116-126.
25. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736.
26. Lenschow D.J., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992, 257(5071):789-792.
27. Perrin P.J., et al. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 1996, 157(4):1333-1336.
28. Hurwitz A.A., et al. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 1997, 73(1-2):57-62.
29. Luhder F., et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 1998, 187(3):427-432.
30. Fife B.T., et al. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. 2006, 116(8):2252-2261.
31. Shieh S.J., et al. Transgenic expression of single-chain anti-CTLA-4 Fv on beta cells protects nonobese diabetic mice from autoimmune diabetes. J. Immunol. 2009, 183(4):2277-2285.
32. Karumuthil-Melethil S., et al. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J. Immunol. 2010, 184(12):6695-6708.
33. Li R., et al. Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J. Immunol. 2007, 179(8):5191-5203.
34. Vasu C., Prabhakar B.S., Holterman M.J. Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J. Immunol. 2004, 173(4):2866-2876.
35. Vasu C., et al. Targeted engagement of CTLA-4 prevents autoimmune thyroiditis. Int. Immunol. 2003, 15(5):641-654.
36. Perez N., et al. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+)-adaptive regulatory T cell generation. J. Immunol. 2008, 180(10):6566-6576.
37. Rao S., et al. Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo. Clin. Immunol. 2001, 101(2):136-145.
38. Thorens B., Roduit R. Regulated expression of GLUT2 in diabetes studied in transplanted pancreatic beta cells. Biochem. Soc. Trans. 1994, 22(3):684-687.
39. Terova G., et al. In vivo regulation of GLUT2 mRNA in sea bass (Dicentrarchus labrax) in response to acute and chronic hypoxia. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2009, 152(4):306-316.
40. Preacher K.J. Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Available from. http://quantpsy.org.
41. Linsley P.S., et al. Immunosuppression in vivo by a soluble form of the CTLA-4T cell activation molecule. Science 1992, 257(5071):792-795.
42. McInerney M.F., Rath S., Janeway C.A. Exclusive expression of MHC class II proteins on CD45+ cells in pancreatic islets of NOD mice. Diabetes 1991, 40(5):648-651.
43. Chen Z., et al. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J. Exp. Med. 2005, 202(10):1387-1397.
44. Chen W., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003, 198(12):1875-1886.
45. Fantini M.C., et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 2004, 172(9):5149-5153.
46. Zheng S.G., et al. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J. Immunol. 2006, 176(6):3321-3329.
47. Barnes M.J., et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol. 2013, 6(2):324-334.